Strategies for the treatment of cancer pain in the new millennium

Drugs

Volumn 61, Issue 7, 2001, Pages 955-977

  Ripamonti, C ^a   Dickerson, E D ^b,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Oxford International Centre for Palliative Care   (United Kingdom)

^c Ohio Pain Inititative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CANNABINOID; DEXTROMETHORPHAN; FENTANYL; GABAPENTIN; KETAMINE; LIDOCAINE; METHADONE; MORPHINE; NICOTINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

CANCER PAIN; CONSTIPATION; DRUG POTENCY; DRUG TOLERABILITY; DRUG USE; HUMAN; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; XEROSTOMIA;

EID: 0034984207     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161070-00005     Document Type: Review

References (248)

1. Cancer pain
2. The prevalence and severity of pain in cancer
3. Epidemiologic features of pain in pediatric cancer patients. A cooperative community-based study
4. Physicians attitudes and practice in cancer pain management
5. A validation study of the WHO method for cancer pain relief
6. Validation of the World Health Organisation guidelines for cancer pain relief. A 10-year prospective study
7. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home
8. Pain and its treatment in outpatients with metastatic cancer
9. Multicentre study of cancer pain and its treatment in France
10. Correlation of patient and care giver ratings of cancer pain
11. Pain relief into practice: Rhetoric without reform
12. Medical students attitudes toward pain before and after a brief course on pain
13. Oncologists and primary care physicians attitudes toward pain control and morphine prescribing in France
14. Opiophobia and cancer pain in Europe
15. Addiction rare in patients treated with narcotics
16. Opioids for chronic cancer and non-cancer pain: A survey of state medical board members
17. Opioid and adjuvant analgesics
18. Morphine in cancer pain: Modes of administration
19. Pharmacological treatment of cancer pain: Alternative routes of opioid administration
20. Opioid responsiveness
21. CNS adverse effects of opioids in cancer patients. Guidelines for treatment
22. Rapid discontinuation of hypnotics in terminal cancer patients: A prospective study
23. The treatment of chronic cancer pain in a cancer hospital in the Netherlands
24. Strategies to manage the adverse effects of oral morphine
25. Antidepressants increase bioavailability of morphine in cancer patients
26. Oral morphine in cancer pain: Influences on morphine and metabolite concentration
27. Myoclonus associated with treatment with high doses of morphine: The role of supplemental drugs
28. Delirium and severe sedation in patients with terminal cancer
29. The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects
30. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healty subjects
31. Organic brain syndromes and opioid administration for cancer pain
32. Normorphine, a neurotoxic metabolite?
33. Chronic nausea and morphine-6-glucuronide
34. Studies on morphine disposition: Influence on renal failure on the kinetics of morphine and its metabolites
35. Plasma levels of morphine and morphine-glucuronides in the treatment of cancer pain: Relationship to renal function and route of administration
36. Systemic review of factors affecting the ratios of morphine and its major metabolites
37. Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration and opioid rotation?
38. Case report: Parenteral hydration of terminally ill cancer patients
39. The use of hypodermoclysis for rehydration in terminally ill cancer patients
40. Indications and ethical considerations in the hydration of patients with advanced cancer
41. Morphine and alternative opioids in cancer pain: The EAPC recommendatios
42. Fentanyl delivery from an electrotransport system: Delivery is a function of total current, not duration of current
43. Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration
44. Palliative care in a cancer center: Results in 1984 versus 1987
45. Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life
46. Epidural and subcutaneous morphine in the management of cancer pain: A double-blind cross-over study
47. Methadone in pain uncontrolled by morphine
48. Individual variability in the response to different opioids: Report of five cases
49. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine
50. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer
51. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: A randomized evaluation
52. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain
53. Role of rectal route in treating cancer pain: A randomized cross-over clinical trial of oral vs rectal morphine administration in opioid-naive cancer patients with pain
54. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial
55. Intraspinal analgesic therapy in palliative care: Evolving perspective
56. Epidural opiates and local anesthetics for the management of cancer pain
57. Problems of long term spinal opioid treatment in advanced cancer patients
58. Epidural clonidine analgesia for intractable cancer pain
59. Opioid treatment for radiating cancer pain: Oral administration vs epidural techniques
60. Morphine-3-glucuronide may functionally antagonize morphine-è-glucuronide induced antinociception and ventilatory depression in the rat
61. Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine
62. Morphine-6-glucuronide, a potent mu agonist
63. Morphine-3-glucuronide: A potent antagonist of morphine analgesia
64. High doses of spinal morphine produced a nonopiate receptor-mediated hyperesthesia: Clinical and theoretic implications
65. Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog
66. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain
67. Opioid-induced itching: Morphine sulfate and hydromorphone hydrochloride
68. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management
69. Opioid rotation for toxicity reduction in terminal cancer patients
70. Disappearance of morphine-induced hyperalgesia after discontinuation or substituting morphine with other opioid agonists
71. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone
72. Severe opioid toxicity and somatization of psychological distress in a cancer patient with a background of chemical dependence
73. Meperidine-induced delirium
74. Acute toxic delirium in a patient using transdermal fentanyl
75. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer
76. Central nervous system excitatory effects of meperidine in cancer patients
77. Myoclonic seizure activity with chronic high-dose spinal opioid administration
78. Opioid hyperexcitability: The application of alternate opioid therapy
79. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
80. Transdermal fentanyl in the long-term treatment of cancer pain: A prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region
81. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: Short-and long-term experiences in a prospective study on 39 patients
82. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine
83. Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS)?
84. Withdrawal with transdermal fentanyl
85. Transdermal fentanyl and the opioid withdrawal syndrome
86. Transdermal fentanyl and the opioid withdrawal syndrome
87. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats
88. Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases
89. Treatment of pain in chronic bowel subobstruction with self-administration of Methadone
90. Opioid type and other clinical predictors of laxative dose in advanced cancer patients
91. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate receptor in rat forebrain and spinal cord
92. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA). Antagonists in the rat cortex and spinal cord
93. New analgesics
94. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home
95. Methadone response in advanced cancer patients with pain followed at home
96. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain
97. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients
98. Patient-controlled analgesia with oral methadone in cancer pain
99. An update on the clinical use of methadone for cancer pain
100. Opioid switching to oral methadone in cancer pain
101. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine
102. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations
103. The use of methadone in cancer pain poorly responsive to other opioids
104. Clinical efficacy of methadone in patients refractory to other mu-opioid receotor agonist analgesics for management of terminal cancer pain
105. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-Receptor
106. NMDA-Receptor antagonists and opioid receptor interactions as related to analgesia and tolerance
107. Current pharmacotherapy of chronic pain
108. NMDA-Receptor antagonists in neuropathic pain: Experimental methods to clinical trials
109. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain
110. Methadone in the management of cancer related neuropathic pain: Report of five cases
111. Methadone in the management of cancer pain: A review
112. Clinical applications of methadone
113. Pharmacological treatment of cancer pain
114. Management of cancer pain
115. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine
116. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio?
117. Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study
118. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences
119. Rapid switching from morphine to methadone in cancer patients with poor response to morphine
120. Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study
121. Breakthrough pain: Definition, prevalence and characteristics
122. Temporal presentation of chronic cancer pain: Transitory pains on admission to a multidisciplinary pain clinic
123. Treatment outcome in a multidisciplinary cancer pain clinic
124. A prospective multi-center assessment of the Edmonton staging system for cancer pain
125. Predictive factors in advanced cancer pain treated only by analgesics
126. Breakthrough pain: Characteristics and impact in patients with cancer pain
127. Malignant bone pain: Pathophysiology and treatments
128. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
129. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
130. The role of bisphopshonates in the treatment of painful metastatic bone disease: A review of phase III trials
131. Current status of patient-controlled analgesia in cancer patients
132. Absorption and bioavailability of oral and transmucosal fentanyl citrate
133. An open label study of oral transmucosal fentanyl citrate (OTFC). For the treatment of breakthrough cancer pain
134. Fentanyl in the treatment of cancer pain
135. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate
136. Dose titration: A multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
137. Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
138. Oral transmucosal fentanyl citrate (OTFC). For the treatment of breakthrough pain in cancer patients: A controlled dose titration study
139. Oral transmucosal fentanyl citrate: A new treatment for breakthrough pain
140. New and alternative noninvasive opioid dosage forms and routes of administration
141. Novel delivery systems: Electrotransport
142. The iontophoresis of fentanyl citrate in humans
143. Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors
144. Cancer pain: Principles of assessment and syndromes
145. An international survey of cancer pain characteristics and syndromes
146. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combained analysis of controlled single dose studies
147. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
148. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
149. Assessment and treatment of neuropathic cancer pain following WHO guidelines
150. Are opioids effective in relieving neuropathic pain?
151. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusion
152. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia
153. Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial
154. Double-blind randomized trial of tramadol for the treatment of pain of diabetic neuropathy
155. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia
156. Randomised double-blind active-controlled crossover trial intravenous fentanyl in neuropathic pain
157. Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design
158. Ineffectiveness of dextromethorphan in cancer pain
159. High-dose dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
160. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats
161. N-Methyl-D-aspartate receptor antagonists potenjtiate morphine's anti-nociceptive effect in the rat
162. MorphiDex (MS:DM). Double-blind, multiple-dose studies in chronic pain patients
163. MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain
164. Long-term safety of Morphi-Dex
165. Ketamine in cancer pain: An update
166. Long-term ketamine subcutaneous infusion in neuropathic cancer pain
167. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient
168. Pain management: Physiopathology, future research and endpoints
169. NMDA receptor blockade in chronic neuropathic pain: A comparison of ketamine and magnesium chloride
170. Intravenous infusion of the NMDA antagonist ketamine, in chronic post-traumatic pain and allodynia: A double-blind comparison to alfentanil and placebo
171. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer
172. Cancer pain: Beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture
173. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: A double-blind, cross-over comparison with morphine and placebo
174. Intravenous lidocaine infusion - A new treatment of chronic painful neuropathy?
175. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy
176. Dercum's disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine
177. Lidocaine as an analgesic for experimental pain
178. Trial of intravenous lidocaine on painful neuropathy in cancer patients
179. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain
180. Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans
181. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain
182. EMLA patch for spinal puncture. A comparison of EMLA patch with lignocaine infiltration and placebo patch
183. Topical EMLA pre-treatment fails to decrease the pain induced by 1% topical capsaicin
184. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia
185. Nonopioid and adjuvant analgesics
186. Association of pain relief with drug side effects in posttherpetic neuralgia: A single-dose study of clonidine, codeine, iburprofen and placebo
187. Aggressive pharmacologic treatment of pain
188. A double-blind comparison between epidural morphine and epidural clonidine in patients with chronic non-cancer pain
189. Role of spinal noradrenergic system in transmission of pain in patients with spinal cord injury
190. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design
191. Postherpetic neuralgia: Response to topical clonidine
192. Practical issues in the management of cancer pain
193. Pharmacological management of pain
194. Adjuvant analgesics in pain management
195. Anticonvulsant drugs for management of pain: A systemic review
196. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs
197. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: A pilot study
198. Gabapentin and S- (+. -3- isobutylgaba represent a novel class of selective anti-hyperalgesic agents
199. Evaluation of gabapentin and S- (+. -3- isobutylgaba in a rat model of post-operative pain
200. Effect of intrathecal gabapentin and 3-isobutyl GABA on the hyperalgesia observed after thermal injury in the rat
201. Characterization of the effects of gabapentin and 3-isobutyl-gamma-aminobutyric acid and substance P-induced thermal hyperalgesia
202. Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test
203. Gabapentin as a novel treatment for postherpetic neuralgia
204. Gabapentin for idiopathic trigeminal neuralgia. Report of two cases
205. Experience with gabapentin for neuropathic pain in the head and neck: Report of ten cases
206. Gabapentin adjunctive therapy in neuropathic pain states
207. Gabapentin and neuropathic pain states: A case series report
208. The effect of gabapentin on neuropathic pain
209. Pain in Guillain-Barre' syndrome
210. Amelioration of refractory dysesthesic limb pain in multiple sclerosis by gabapentin
211. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial
212. Gabapentin for the treatment of Postherpetic Neuralgia. A randomized controlled trial
213. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain
214. Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam and acetylsalicylic acid plus codeina in chronic cancer pain
215. Paracetamol with and without codeine in acute pain: A quantitative systematic review
216. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability
217. Potentiation of pentazocine analgesia by low-dose naloxone
218. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulphate
219. A range of research-based pharmacotherapies for addiction
220. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice
221. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia
222. Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonist
223. Antinociception produced by receptor selective opioids. Modulation of supraspinal antinociceptive effects by spinal opioids
224. The intrinsic antinociceptive effects of oxycodone appear to be kappa opioid receptor mediated
225. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats
226. Cannabis: Time for scientific evaluation of this ancient remedy?
227. Palliation of nausea and vomiting
228. The role of endogenous opioids in enhancing the antinociception produced by the combination of Delta-9-tetrahydrocannabinol and morphine in the spinal cord
229. Cannabinoids as potential new analgesics
230. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
231. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
232. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
233. Control of pain initiation by endogenous cannabinoids
234. Anti-hyperalgesic effects of spinal cannabinoids
235. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation
236. The analgesic effects of R (+. - WIN 55.212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
237. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheal CBI receptors
238. A comparison of THC, nantradol, nabilone and morphine in the chronic spinal dog
239. The analgesic properties of delta-9-tetrahydrocannibinol and codeine
240. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats
241. Effect of noncompetitive nicotinic receptor blockers on catecholamine release from cultured adrenal chromaffin cells
242. Sympathoadrenal contribution to nicotinic and muscarinic modulation of bradykinin plasma extravasation in the knee joint of the rat
243. Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics
244. Peripheral neural contributions to inflammation